Simple cycle review framework Review point Baseline What to check Research goal, measurements, route, and materials Reason Creates a clear starting point Review point Week 4 What to check Tolerance, handling, and protocol consistency Reason Finds early problems Review point Week 8 What to check Trend compared with baseline Reason Tests whether the plan is producing useful data Review point Week 12 What to check Full review of benefits, limits, and uncertainty Reason Prevents an automatic extension Review point Week 16 or later What to check Reason for continuing and remaining evidence gaps Reason Longer subcutaneous timelines are not clinically established When a Longer Cycle Is Not Supported There is no published evidence showing that extending AOD-9604 beyond 12 or 16 weeks improves the outcome of a community subcutaneous plan
The realistic ways it could affect weight (indirectly) When evaluating weight-loss claims, it's helpful to think in terms of systems rather than slogans
Journal Impact Factor = 1.75, Times Cited = 11 (ResearchGate) Mcgilveray, Iain J
No trial has randomised the same population to both compounds
With proper administration and follow-up , most patients experience minimal to no prolonged discomfort during NAD+ post-procedure recovery